Comparison of modified corneal cross-linking with intrastromal voriconazole for the treatment of fungal corneal ulcer

Chen,Yingxin; Miao,Xingya; Gao,Minghong; Song,Lixin

doi:10.3892/etm.2021.10218

Comparison of modified corneal cross-linking with intrastromal voriconazole for the treatment of fungal corneal ulcer

Authors:
- Yingxin Chen
- Xingya Miao
- Minghong Gao
- Lixin Song
View Affiliations

Affiliations: Department of Ophthalmology, General Hospital of Northern Theater Command, Shenyang, Liaoning 110016, P.R. China, Department of Dermatology, General Hospital of Northern Theater Command, Shenyang, Liaoning 110016, P.R. China
Published online on: May 21, 2021 https://doi.org/10.3892/etm.2021.10218
Article Number: 786
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to evaluate the efficacy of modified corneal cross‑linking (CXL) for the treatment of fungal corneal ulcers compared with that following intrastromal voriconazole injection. In total, 31 patients with fungal corneal ulcers treated at The General Hospital of Northern Theater Command between October 2017 and October 2019 were enrolled. Among them, 10 eyes were treated with ultraviolet A (UV‑A)/riboflavin CXL (CXL group), whilst 21 eyes were treated with debridement combined with intrastromal voriconazole (stromal injection group). Preoperative microbiological examination was performed in both groups, and evaluated using Fisher's exact test. Postoperatively, infection control and total efficacy rates, localized lesion, ulcer healing rate 1 week after surgery, visual acuity and complications were evaluated using Fisher's exact test, however visual acuity was analyzed by mixed‑model ANOVA. The results showed that the pre‑operative species distribution between the CXL and stromal injection groups did not significantly differ. The infection control rate in the CXL group was notably higher compared with that in the stromal injection group (P=0.04). Furthermore, the total efficacy rate in the CXL group was also markedly higher compared with that in the stromal injection group, though no statistically significant differences were observed. Localized lesions were observed in nine eyes (90.0%) in the CXL group and nine eyes (42.9%) in the stromal injection group (P=0.02). However, the rate of ulcer healing at 1 week postoperatively and the logarithm of the minimum angle of resolution (logMAR) of visual acuity were not found to be significantly different between the two groups. In terms of complications, with the exception of one patient in the CXL group exhibiting loss of corneal transparency and one patient in the stromal injection group presenting with partial corneal thinning, no other forms of complications were observed. In conclusion, the present study suggested that CXL could have a beneficial impact for treating fungal corneal ulcers in the aspects of infection control, localized lesions and accelerated epithelialization. In addition, except the loss of corneal transparency, this treatment approach could be applied with reduced risks of adverse events.

View Figures

View References

1	Wang L, Sun S, Jing Y, Han L, Zhang H and Yue J: Spectrum of fungal keratitis in central China. Clin Exp Ophthalmol. 37:763–771. 2009.PubMed/NCBI View Article : Google Scholar
2	Wu J, Zhang WS, Zhao J and Zhou HY: Review of clinical and basic approaches of fungal keratitis. Int J Ophthalmol. 9:1676–1683. 2016.PubMed/NCBI View Article : Google Scholar
3	Fini ME, Cook JR and Mohan R: Proteolytic mechanisms in corneal ulceration and repair. Arch Dermatol Res. 290 (Suppl 1):S12–S23. 1998.PubMed/NCBI View Article : Google Scholar
4	Xie L, Zhong W, Shi W and Sun S: Spectrum of fungal keratitis in north China. Ophthalmology. 113:1943–1948. 2006.PubMed/NCBI View Article : Google Scholar
5	Chen Y, Yang W, Gao M, Belin MW, Yu H and Yu J: Experimental study on cryotherapy for fungal corneal ulcer. BMC Ophthalmol. 15(29)2015.PubMed/NCBI View Article : Google Scholar
6	Garg P, Roy A and Roy S: Update on fungal keratitis. Curr Opin Ophthalmol. 27:333–339. 2016.PubMed/NCBI View Article : Google Scholar
7	Spoerl E, Mrochen M, Sliney D, Trokel S and Seiler T: Safety of UVA-riboflavin cross-linking of the cornea. Cornea. 26:385–389. 2007.PubMed/NCBI View Article : Google Scholar
8	Zhang Y, Conrad AH and Conrad GW: Effects of ultraviolet-A and riboflavin on the interaction of collagen and proteoglycans during corneal cross-linking. J Biol Chem. 286:13011–13022. 2011.PubMed/NCBI View Article : Google Scholar
9	Wei S, Zhang C, Zhang S, Xu Y and Mu G: Treatment results of corneal collagen cross-linking combined with riboflavin and 440 Nm blue light for bacterial corneal ulcer in rabbits. Curr Eye Res. 42:1401–1406. 2017.PubMed/NCBI View Article : Google Scholar
10	Tal K, Gal-Or O, Pillar S, Zahavi A, Rock O and Bahar I: Efficacy of primary collagen cross-linking with photoactivated chromophore (PACK-CXL) for the treatment of staphylococcus aureus-induced corneal ulcers. Cornea. 34:1281–1286. 2015.PubMed/NCBI View Article : Google Scholar
11	Raiskup F and Spoerl E: Corneal crosslinking with riboflavin and ultraviolet A. I. Principles. Ocul Surf. 11:65–74. 2013.PubMed/NCBI View Article : Google Scholar
12	Ghanem VC, Ghanem RC and de Oliveira R: Postoperative pain after corneal collagen cross-linking. Cornea. 32:20–24. 2013.PubMed/NCBI View Article : Google Scholar
13	Taneri S, Oehler S, Lytle G and Dick HB: Evaluation of epithelial integrity with various transepithelial corneal cross-linking protocols for treatment of keratoconus. J Ophthalmol. 2014(614380)2014.PubMed/NCBI View Article : Google Scholar
14	Lombardo M, Giannini D, Lombardo G and Serrao S: Randomized controlled trial comparing transepithelial corneal cross-linking using iontophoresis with the dresden protocol in progressive keratoconus. Ophthalmology. 124:804–812. 2017.PubMed/NCBI View Article : Google Scholar
15	Kim M, Takaoka A, Hoang QV, Trokel SL and Paik DC: Pharmacologic alternatives to riboflavin photochemical corneal cross-linking: A comparison study of cell toxicity thresholds. Invest Ophthalmol Vis Sci. 55:3247–3257. 2014.PubMed/NCBI View Article : Google Scholar
16	Gatzioufas Z, Richoz O, Brugnoli E and Hafezi F: Safety profile of high-fluence corneal collagen cross-linking for progressive keratoconus: Preliminary results from a prospective cohort study. J Refract Surg. 29:846–848. 2013.PubMed/NCBI View Article : Google Scholar
17	Chan TC, Chow VW, Jhanji V and Wong VW: Different topographic response between mild to moderate and advanced keratoconus after accelerated collagen cross-linking. Cornea. 34:922–927. 2015.PubMed/NCBI View Article : Google Scholar
18	Özdemir HB, Kalkancı A, Bilgihan K, Göçün PU, Öğüt B, Karakurt F and Erdoğan M: Comparison of corneal collagen cross-linking (PACK-CXL) and voriconazole treatments in experimental fungal keratitis. Acta Ophthalmol. 97:e91–e96. 2019.PubMed/NCBI View Article : Google Scholar
19	Jorgensen JH, Pfaller MA, Carroll KC, Funke G, Landry ML, Richter SR and Warnock DW (eds): Manual of Clinical Microbiology. 11th edition. American Society for Microbiology, p2892, 2015.
20	Mutoh T, Ishikawa I, Matsumoto Y and Chikuda M: A retrospective study of nine cases of Acanthamoeba keratitis. Clin Ophthalmol. 4:1189–1192. 2010.PubMed/NCBI View Article : Google Scholar
21	Karti O, Zengin MO, Cinar E, Tutuncu M, Karahan E, Celik A and Kucukerdonmez C: Effect of 1- and 6-hour-delayed corneal collagen cross-linking on corneal healing in a rabbit alkali-burn model: Clinical and histological observations. Cornea. 35:1644–1649. 2016.PubMed/NCBI View Article : Google Scholar
22	Sharma S: Diagnosis of infectious diseases of the eye. Eye (Lond). 26:177–184. 2012.PubMed/NCBI View Article : Google Scholar
23	Bamdad S, Malekhosseini H and Khosravi A: Ultraviolet A/riboflavin collagen cross-linking for treatment of moderate bacterial corneal ulcers. Cornea. 34:402–406. 2015.PubMed/NCBI View Article : Google Scholar
24	Kohlhaas M, Spoerl E, Schilde T, Unger G, Wittig C and Pillunat LE: Biomechanical evidence of the distribution of cross-links in corneas treated with riboflavin and ultraviolet A light. J Cataract Refract Surg. 32:279–283. 2006.PubMed/NCBI View Article : Google Scholar
25	Spoerl E, Wollensak G and Seiler T: Increased resistance of crosslinked cornea against enzymatic digestion. Curr Eye Res. 29:35–40. 2004.PubMed/NCBI View Article : Google Scholar
26	Kasparova EA, Sobkova OI and Yang B: Corneal collagen cross-linking in the treatment of infectious keratitis and corneal ulcers. Vestn Oftalmol. 133:113–119. 2017.PubMed/NCBI View Article : Google Scholar : (In Russian).
27	Lakhundi S, Siddiqui R and Khan NA: Pathogenesis of microbial keratitis. Microb Pathog. 104:97–109. 2017.PubMed/NCBI View Article : Google Scholar
28	Hariprasad SM, Mieler WF, Lin TK, Sponsel WE and Graybill JR: Voriconazole in the treatment of fungal eye infections: A review of current literature. Br J Ophthalmol. 92:871–878. 2008.PubMed/NCBI View Article : Google Scholar
29	Siatiri H, Daneshgar F, Siatiri N and Khodabande A: The effects of intrastromal voriconazole injection and topical voriconazole in the treatment of recalcitrant Fusarium keratitis. Cornea. 30:872–875. 2011.PubMed/NCBI View Article : Google Scholar
30	Prakash G, Sharma N, Goel M, Titiyal JS and Vajpayee RB: Evaluation of intrastromal injection of voriconazole as a therapeutic adjunctive for the management of deep recalcitrant fungal keratitis. Am J Ophthalmol. 146:56–59. 2008.PubMed/NCBI View Article : Google Scholar
31	Li SX, Biang J, Li X, Zhang LT and Shi WY: Keratectomy combined with intrastromal injection of voriconazole in treating fungal keratitis. Zhonghua Yan Ke Za Zhi. 53:682–688. 2017.PubMed/NCBI View Article : Google Scholar : (In Chinese).
32	Narayana S, Krishnan T, Ramakrishnan S, Samantaray PP, Austin A, Pickel J, Porco T, Lietman T and Rose-Nussbaumer J: Mycotic antimicrobial localized injection: A randomized clinical trial evaluating intrastromal injection of voriconazole. Ophthalmology. 126:1084–1089. 2019.PubMed/NCBI View Article : Google Scholar
33	Niki M, Eguchi H, Hayashi Y, Miyamoto T, Hotta F and Mitamura Y: Ineffectiveness of intrastromal voriconazole for filamentous fungal keratitis. Clin Ophthalmol. 8:1075–1079. 2014.PubMed/NCBI View Article : Google Scholar
34	Lin HC, Chu PH, Kuo YH and Shen SC: Clinical experience in managing Fusarium solani keratitis. Int J Clin Pract. 59:549–554. 2005.PubMed/NCBI View Article : Google Scholar
35	Cheng J, Zhai HL, Wang JY and Xie LX: Clinical features and treatments of retrocorneal fungal infection. Zhonghua Yan Ke Za Zhi. 53:758–765. 2017.PubMed/NCBI View Article : Google Scholar
36	Schacter LP, Owellen RJ, Rathbun HK and Buchanan B: Letter: Antagonism between miconazole and amphotericin B. Lancet. 2(318)1976.PubMed/NCBI View Article : Google Scholar
37	Shen YC, Wang MY, Wang CY, Tsai TC, Tsai HY, Lee HN and Wei LC: Pharmacokinetics of intracameral voriconazole injection. Antimicrob Agents Chemother. 53:2156–2157. 2009.PubMed/NCBI View Article : Google Scholar
38	Alastruey-Izquierdo A, Cuenca-Estrella M, Monzón A, Mellado E and Rodríguez-Tudela JL: Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods. J Antimicrob Chemother. 61:805–809. 2008.PubMed/NCBI View Article : Google Scholar
39	Pearson MM, Rogers PD, Cleary JD and Chapman SW: Voriconazole: A new triazole antifungal agent. Ann Pharmacother. 37:420–432. 2003.PubMed/NCBI View Article : Google Scholar
40	Kashiwabuchi RT, Carvalho FR, Khan YA, Hirai F, Campos MS and McDonnell PJ: Assessment of fungal viability after long-wave ultraviolet light irradiation combined with riboflavin administration. Graefes Arch Clin Exp Ophthalmol. 251:521–527. 2013.PubMed/NCBI View Article : Google Scholar
41	Bilgihan K, Kalkanci A, Ozdemir HB, Yazar R, Karakurt F, Yuksel E, Otag F, Karabicak N and Arikan-Akdagli S: Evaluation of antifungal efficacy of 0.1% and 0.25% riboflavin with UVA: A comparative in vitro study. Curr Eye Res. 41:1050–1056. 2016.PubMed/NCBI View Article : Google Scholar
42	Li Z, Jhanji V, Tao X, Yu H, Chen W and Mu G: Riboflavin/ultravoilet light-mediated crosslinking for fungal keratitis. Br J Ophthalmol. 97:669–671. 2013.PubMed/NCBI View Article : Google Scholar
43	Kling S, Hufschmid FS, Torres-Netto EA, Randleman JB, Willcox M, Zbinden R and Hafezi F: High fluence increases the antibacterial efficacy of PACK cross-linking. Cornea. 39:1020–1026. 2020.PubMed/NCBI View Article : Google Scholar
44	Wu CS, Wu SS and Chen PC: A prospective study of fungal infection of gastric ulcers: Clinical significance and correlation with medical treatment. Gastrointest Endosc. 42:56–58. 1995.PubMed/NCBI View Article : Google Scholar
45	Idrus EA, Utti EM and Mattila JS: Photoactivated chromophore corneal cross-linking (PACK-CXL) for treatment of severe keratitis. Acta Ophthalmol. 97:721–726. 2019.PubMed/NCBI View Article : Google Scholar
46	Said DG, Elalfy MS, Gatzioufas Z, El-Zakzouk ES, Hassan MA, Saif MY, Zaki AA, Dua HS and Hafezi F: Collagen cross-linking with photoactivated riboflavin (PACK-CXL) for the treatment of advanced infectious keratitis with corneal melting. Ophthalmology. 121:1377–1382. 2014.PubMed/NCBI View Article : Google Scholar
47	You X, Li J, Li S and Shi W: Effects of lamellar keratectomy and intrastromal injection of 0.2% fluconazole on fungal keratitis. J Ophthalmol. 2015(656027)2015.PubMed/NCBI View Article : Google Scholar
48	Wollensak G, Spoerl E, Wilsch M and Seiler T: Keratocyte apoptosis after corneal collagen cross-linking using riboflavin/UVA treatment. Cornea. 23:43–49. 2004.PubMed/NCBI View Article : Google Scholar
49	Linna TU, Vesaluoma MH, Petroll WM, Tarkkanen AH and Tervo TM: Confocal microscopy of a patient with irregular astigmatism after LASIK reoperations and relaxation incisions. Cornea. 19:163–169. 2000.PubMed/NCBI View Article : Google Scholar
50	Sivak JM and Fini ME: MMPs in the eye: Emerging roles for matrix metalloproteinases in ocular physiology. Prog Retin Eye Res. 21:1–14. 2002.PubMed/NCBI View Article : Google Scholar